Five years ago, Companion DX Reference Lab hoped to cash in oncutting-edge genetic tests paid for by Medicare.

The Houston lab marketed a test to assess how a person’s genesaffect tolerance for drugs such as opiates used to treat chronicpain. It also ran DNA tests to help treat cancer and urine screens to monitor drug abuse.

But the lab went bust last year after Medicare ordered it torepay more than $16 million for genetic tests health officials saidwere not needed.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.